Canada Plans Parallel HTA And Marketing Authorization Reviews
Canada plans to run regulatory reviews and health technology appraisals in parallel for certain new medicines. This could mean some companies get their drugs listed on public health plans almost immediately upon market authorization, rather than having to wait for more than a year.
You may also be interested in...
Drug sponsors can opt into the newly launched Canadian parallel review scheme at any stage of the marketing authorization review process, but the earlier they do so the better.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.